Journal Title：Blood

Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.

Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to contact the Editor-in-Chief prior to submission if they are uncertain whether their work falls within the general scope of the journal.

《血液》是美國血液學會的官方期刊，以在線和印刷形式出版，為發(fā)表描述血液學基礎實驗室、轉化和臨床研究的原創(chuàng)文章提供了一個國際論壇。稿件的接受基于觀察或調查的原創(chuàng)性和重要性、工作質量和證據的有效性、表達的清晰度以及與讀者和領域的相關性。所有文章都應簡潔、組織良好且寫得清楚。作者提交稿件時應了解稿件（或其基本內容）未以任何語言或格式以摘要以外的形式發(fā)表過，并且目前未提交給其他地方進行印刷或電子出版。

主要研究文章將發(fā)表在以下科學類別下：臨床試??驗和觀察；基因治療；造血和干細胞；免疫生物學和免疫治療范圍；髓系腫瘤；淋巴系腫瘤；吞噬細胞、粒細胞和髓系細胞生成；血小板和血栓形成；紅細胞、鐵和紅細胞生成；血栓形成和止血；輸血醫(yī)學；移植；血管生物學。論文可以根據需要列在多個類別下。如果作者不確定他們的工作是否屬于該期刊的一般范圍，請在提交前聯(lián)系主編。

Blood創(chuàng)刊于1946年，由American Society of Hematology出版商出版，收稿方向涵蓋醫(yī)學 - 血液學全領域，在行業(yè)領域中學術影響力很大，屬于TOP期刊，國際一流期刊，關注度和專業(yè)度非常高，所以對原創(chuàng)文章要求創(chuàng)新性很高，過審難度很高，如果您有志于TOP期刊，建議關注此刊。平均審稿速度 約1.0個月 ，影響因子指數21，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。